FibroBiologics Expands Platform to Target Hantavirus Pulmonary Syndrome

FibroBiologics, Inc. announced a strategic expansion of its fibroblast-based platform to target Hantavirus pulmonary syndrome (HPS). This initiative builds on existing preclinical work in treating acute respiratory distress syndrome (ARDS), which shares similar terminal lung damage and inflammatory cascades with HPS. HPS is a rare but severe respiratory illness with high mortality rates and no approved antiviral therapies. The company's fibroblast platform is designed to modulate uncontrolled inflammatory responses and promote tissue repair, and FibroBiologics is now evaluating its platform in Hantavirus disease models with plans for regulatory discussions.